Prima Biomed in trading halt
Tuesday, 17 November, 2009
Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.
Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.
Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.
Prima Biomed shares were last trading at 16.5c.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
